These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 9310955)

  • 1. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas.
    Kanter-Lewensohn L; Hedblad MA; Wejde J; Larsson O
    Mod Pathol; 1997 Sep; 10(9):917-20. PubMed ID: 9310955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
    Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
    Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S100A6 protein expression is different in Spitz nevi and melanomas.
    Ribé A; McNutt NS
    Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell cycle and apoptosis regulators in Spitz nevi: comparison with melanomas and common nevi.
    Stefanaki C; Stefanaki K; Antoniou C; Argyrakos T; Patereli A; Stratigos A; Katsambas A
    J Am Acad Dermatol; 2007 May; 56(5):815-24. PubMed ID: 17437889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions.
    Chorny JA; Barr RJ; Kyshtoobayeva A; Jakowatz J; Reed RJ
    Mod Pathol; 2003 Jun; 16(6):525-9. PubMed ID: 12808056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
    Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
    J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of c-kit (CD117) in Spitz nevus and malignant melanoma.
    Isabel Zhu Y; Fitzpatrick JE
    J Cutan Pathol; 2006 Jan; 33(1):33-7. PubMed ID: 16441409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MIB-1 monoclonal antibody to determine proliferative activity of Ki-67 antigen as an adjunct to the histopathologic differential diagnosis of Spitz nevi.
    Bergman R; Malkin L; Sabo E; Kerner H
    J Am Acad Dermatol; 2001 Mar; 44(3):500-4. PubMed ID: 11209122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Bayes rule and MIB-1 proliferation index to discriminate Spitz nevus from malignant melanoma.
    Vollmer RT
    Am J Clin Pathol; 2004 Oct; 122(4):499-505. PubMed ID: 15487445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin D1 overexpression in Spitz nevi: an immunohistochemical study.
    Nagasaka T; Lai R; Medeiros LJ; Brynes RK; McCourty A; Harada T; Saddik M
    Am J Dermatopathol; 1999 Apr; 21(2):115-20. PubMed ID: 10218669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors.
    Vargas MP; Vargas HI; Kleiner DE; Merino MJ
    Mod Pathol; 1997 Jan; 10(1):12-7. PubMed ID: 9021722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
    Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
    Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silhouette symmetry: an unsupportable histologic criterion for distinguishing Spitz nevi and compound nevi from malignant melanoma.
    Okun MR
    Arch Pathol Lab Med; 1997 Jan; 121(1):48-53. PubMed ID: 9111092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. bcl-2 protein expression in melanocytic neoplasms of the skin.
    Ramsay JA; From L; Kahn HJ
    Mod Pathol; 1995 Feb; 8(2):150-4. PubMed ID: 7777475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of cell cycle and apoptosis regulatory proteins and telomerase in melanocitic lesions.
    Batinac T; Hadzisejdić I; Brumini G; Ruzić A; Vojniković B; Zamolo G
    Coll Antropol; 2007 Jan; 31 Suppl 1():17-22. PubMed ID: 17469743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas.
    Jensen V; Sørensen FB; Bentzen SM; Ladekarl M; Nielsen OS; Keller J; Jensen OM
    Histopathology; 1998 Jun; 32(6):536-46. PubMed ID: 9675593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of p16 alone does not differentiate between Spitz nevi and Spitzoid melanoma.
    Mason A; Wititsuwannakul J; Klump VR; Lott J; Lazova R
    J Cutan Pathol; 2012 Dec; 39(12):1062-74. PubMed ID: 23005921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions.
    Li LX; Crotty KA; McCarthy SW; Palmer AA; Kril JJ
    Am J Dermatopathol; 2000 Dec; 22(6):489-95. PubMed ID: 11190439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.